FDA approves Siliq (brodalumab) for psoriasis

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

FDA approved Siliq (brodalumab), as an injection for the treatment of adults with moderate-to-severe plaque psoriasis. Siliq is intended for patients receiving systemic therapy or phototherapy and have failed to respond other systemic therapies.

Psoriasis is an autoimmune disorder which more commonly occurs in patients with a family history of the disease and most often in people 15 to 35 years of age. Psoriasis cause patches of red skin and flakes. Plaque psoriasis is most common form of psoriasis causing thick, red flaky skin, silver-white scales.

Brodalumab inhibits the inflammatory response responsible for the development of plaque psoriasis by binding to a protein which cause inflammation.

The safety and efficacy of Siliq was established in 3 randomized, placebo-controlled clinical trials of 4,373 adult participants with moderate-to-severe plaque psoriasis who received systemic therapy or phototherapy. Patients treated with Siliq had clear or almost clear skin compared to placebo as evaluated by scoring of the e...

Recommended for you

  • FDA Drug Updates
  • 1 comment

FDA approved Brineura (cerliponase alfa) for Batten disease

Read more
  • FDA Drug Updates
  • 1 comment

FDA expands approved use of Stivarga (regorafinib) for liver cancer

Read more
  • MedWatch Drug Updates
  • no comment

Recall of 25% Dextrose Injection, USP, (Infant) by Hospira- Presence of particulate matter

Read more
  • MedWatch Drug Updates
  • 1 comment

Drug safety alert: New warning on use of anesthetic/sedation drugs in young children, pregnant women

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA warning- Illegal selling of products that fraudulently claim to prevent, diagnose, treat or cure cancer

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Phenobarbital tablets, USP, 15 mg by C.O. Truxton- Mislabeling with incorrect strength

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Ingrezza (valbenazine) for tardive dyskinesia

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA restricts use of codeine and tramadol in children and breastfeeding women-Risk of serious adverse reactions

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Ocrevus (ocrelizumab) for multiple sclerosis

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Zejula (niraparib) for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

Read more
  • FDA Drug Updates
  • 1 comment

FDA approves Dupixent (dupilumab) for atopic dermatitis

Read more
  • FDA Drug Updates
  • no comment

FDA approved Bavencio (avelumab) for Merkel cell carcinoma

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Xadago (safinamide) for Parkinson’s disease

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Homeopathic Baby Teething products by Hyland- Elevated levels of belladonna

Read more
  • MedWatch Drug Updates
  • no comment

Recall of the StrataMR adjustable valves and shunts by Medtronic- Under-drainage of CSF post-implantation

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Odactra for house dust mite allergies

Read more
  • FDA Drug Updates
  • 1 comment

Approval of Xermelo (telotristat ethyl) for carcinoid syndrome diarrhea

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of sterile products by Isomeric Pharmacy Solutions- Lack of sterility assurance

Read more
  • MedWatch Drug Updates
  • 1 comment

Field corrective action for Newport HT70 and HT70 Plus ventilators by Medtronic -Ventilators may reset spontaneously

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of EpiPen and EpiPen Jr Auto-Injector- Failure to activate device due to defect in a supplier component

Read more
  • FDA Drug Updates
  • 1 comment

FDA approves Siliq (brodalumab) for psoriasis

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Parsabiv (etelcalcetide) for hyperparathyroidism in dialysis patients

Read more
  • FDA Drug Updates
  • 1 comment

FDA approval of Emflaza (deflazacort) for duchenne muscular dystrophy

Read more
  • MedWatch Drug Updates
  • no comment

Class I Recall : HeartStart MRx Monitor/Defibrillator by Phillips - Electrical and battery connection issue

Read more
  • FDA Drug Updates
  • 1 comment

Approval of Trulance (plecanatide) for chronic idiopathic constipation

Read more
  • MedWatch Drug Updates
  • no comment

FDA safety alert - Absorb GT1 Bioresorbable Vascular Scaffold associated with increased risk of CV events

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA Safety Alert: breast implants associated with risk of developing anaplastic large cell lymphoma

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of SynchroMed Implantable Infusion Pump by Medtronic due to hindered drug delivery during priming bolus procedure

Read more
  • FDA Drug Updates
  • 1 comment

First drug approved for treatment of spinal muscular atrophy

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Rubraca (rucaparib) for BRCA+ advanced ovarian cancer

Read more